Alpha Emitter Market to Witness a CAGR of 23.44% during 2020 to 2026 Globally – Axiom MRC

Wilmington, July 22, 2020: Axiom Market Research & Consulting™ published a report on global alpha emitter market which includes study on radionuclide type, medical application, end user across various countries of key regions across the globe. The global alpha emitter market was projected to grow at a CAGR of 23.44% for the forecast period 2020 to 2026. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the alpha emitter market.

Download Sample Report: https://www.axiommrc.com/requested_sample/1717-alpha-emitters-market-report

The report analyses the global alpha emitters market based on radionuclide type, medical application, end user and geography. Various radionuclide type studied are segmented into Actinium (Ac-225), Astatine (At-211), Bismuth (Bi -213), Bismuth (Bi-212), Lead (Pb-212), Radium (Ra-223) and Terbium (Tb-149). The medical application segment is categorized into prostate cancer, bone metastases, ovarian cancer, pancreatic cancer, endocrine tumors and others. Furthermore, the major end users considered in the study are hospitals, clinics and research laboratories. The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World.

The major players operating in the alpha emitter market include Actinium Pharmaceuticals (United States), Alpha Tau Medical (Israel), Bayer AG (Germany), Fusion Pharmaceuticals Inc. (Canada), IBA RadioPharma Solutions (Belgium), Orano Med (France), Plexus Corp. (Columbia), RadioMedix, Inc. (United States) and Telix Pharmaceuticals Ltd (Australia).

Browse for More Details: https://www.axiommrc.com/product/1717-alpha-emitters-market-report

Alpha Emitter Market Regional Trends
North America accounted for the largest market share in 2019 in terms of revenue followed by Europe. Owing to the fact that the increase in oncology and neurological chronic diseases is the major driving factor for the market growth in the NA region. Moreover, the Asia Pacific alpha emitters market is anticipated to grow at a fastest growth rate during the forecast period. Over the forecast period, the phenomenon anticipated to boost market expansion, is the rise in number of healthcare facilities and improvement in care provision.

Alpha Emitter Market Segmental Highlights:

• The Radium (Ra-223) segment dominated the global alpha emitters market in 2019
• Increase in awareness of the potential benefits of targeted alpha emitter and high number of patients with various types of cancers such as ovarian cancer, pancreatic cancer, lymphoma, and melanoma are likely to augment market growth
• The ovarian cancer segment dominated the global alpha emitters market, by medical application in 2019
• Use of targeted anticancer or alpha therapy (TAT) in the treatment of cancer and alpha particles to boost growth
• In addition, increasing use of targeted anticancer or alpha therapy (TAT) in the treatment of cancer and alpha particles has an advantage in targeted therapy because of their exceptionally high cell-killing ability. Ovarian cancer uses radio immunotherapy as locally injected adjuvant therapy

Research Objectives of Alpha Emitter Market Report:

• Analyzing the outlook of the market with the recent trends and Porter’s five forces analysis.
• Market dynamics, which essentially consider the factors that are impelling the present market scenario, along with growth prospects of the market over the forecast period.
• Market segmentation analysis, including qualitative and quantitative research, incorporating the impact of economic and non-economic aspects.
• Country-level analysis, integrating the demand and supply forces that are influencing the growth of the Alpha Emitter Market.
• Competitive landscape involving the market share of major players, along with the key strategies adopted for development over the past five years.
• Comprehensive company profiles, covering the product offerings, key financial information, recent developments and strategies employed by the major market players

Our Other Related Reports:

Nuclear Medicine Market Report:
https://axiommrc.com/product/1689-nuclear-medicine-market-report

Biosimilars Market
https://axiommrc.com/product/hc1859-biosimilars-market-report

Contact Us:
Ganesh Sai
United States
3 Germay Dr. Ste 4 - 4666
Wilmington DE 19804
U.S.:- + 1 (845) 875-9786
U.K.:- + 44 (0) 20 3286 9707
Email: sales@axiommrc.com

About Us:
Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc.

Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.

Axiom MRC with its experienced team of research and data analysts, has delivered more than 700+ Market Research Projects, 2100+ Data Analytics Projects, 260+ Business Support Projects and has a 400+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.

For more information, visit Axiom Market Research & Consulting™ at www.axiommrc.com

This release was published on openPR.